ID   MARK2_HUMAN             Reviewed;         788 AA.
AC   Q7KZI7; Q15449; Q15524; Q5XGA3; Q68A18; Q96HB3; Q96RG0;
DT   12-APR-2005, integrated into UniProtKB/Swiss-Prot.
DT   12-APR-2005, sequence version 2.
DT   12-OCT-2022, entry version 181.
DE   RecName: Full=Serine/threonine-protein kinase MARK2;
DE            EC=2.7.11.1;
DE            EC=2.7.11.26;
DE   AltName: Full=ELKL motif kinase 1;
DE            Short=EMK-1;
DE   AltName: Full=MAP/microtubule affinity-regulating kinase 2;
DE   AltName: Full=PAR1 homolog;
DE   AltName: Full=PAR1 homolog b;
DE            Short=Par-1b;
DE            Short=Par1b;
GN   Name=MARK2 {ECO:0000312|EMBL:AAH08771.2}; Synonyms=EMK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:CAA66229.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 3), AND TISSUE SPECIFICITY.
RC   TISSUE=Colon {ECO:0000312|EMBL:CAA66229.1};
RX   PubMed=9730619; DOI=10.1159/000015046;
RA   Espinosa L., Navarro E.;
RT   "Human serine/threonine protein kinase EMK1: genome structure and cDNA
RT   cloning of isoforms produced by alternative splicing.";
RL   Cytogenet. Cell Genet. 81:278-282(1998).
RN   [2] {ECO:0000305, ECO:0000312|EMBL:BAD37141.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5).
RC   TISSUE=Kidney {ECO:0000312|EMBL:CAA66229.1};
RA   Sugiyama A., Inoue H., Oka M.;
RL   Submitted (AUG-2004) to the EMBL/GenBank/DDBJ databases.
RN   [3] {ECO:0000305, ECO:0000312|EMBL:BAD37141.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 6).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [5] {ECO:0000305, ECO:0000312|EMBL:AAH08771.2}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4), AND NUCLEOTIDE SEQUENCE
RP   [LARGE SCALE MRNA] OF 11-755 (ISOFORM 1).
RC   TISSUE=Kidney {ECO:0000312|EMBL:AAH84540.1}, and Placenta
RC   {ECO:0000312|EMBL:AAH08771.2};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6] {ECO:0000305, ECO:0000312|EMBL:AAK82368.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 28-788 (ISOFORM 4), AND FUNCTION.
RX   PubMed=11433294; DOI=10.1038/35083016;
RA   Sun T.-Q., Lu B., Feng J.-J., Reinhard C., Jan Y.N., Fantl W.J.,
RA   Williams L.T.;
RT   "PAR-1 is a Dishevelled-associated kinase and a positive regulator of Wnt
RT   signalling.";
RL   Nat. Cell Biol. 3:628-636(2001).
RN   [7] {ECO:0000305, ECO:0000312|EMBL:CAA80914.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 190-237.
RX   PubMed=8274451;
RA   Schultz S.J., Nigg E.A.;
RT   "Identification of 21 novel human protein kinases, including 3 members of a
RT   family related to the cell cycle regulator nimA of Aspergillus nidulans.";
RL   Cell Growth Differ. 4:821-830(1993).
RN   [8]
RP   FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=12429843; DOI=10.1091/mbc.02-03-0046;
RA   Biernat J., Wu Y.Z., Timm T., Zheng-Fischhofer Q., Mandelkow E., Meijer L.,
RA   Mandelkow E.M.;
RT   "Protein kinase MARK/PAR-1 is required for neurite outgrowth and
RT   establishment of neuronal polarity.";
RL   Mol. Biol. Cell 13:4013-4028(2002).
RN   [9] {ECO:0000305}
RP   FUNCTION, AND ALTERNATIVE PROMOTER USAGE.
RX   PubMed=15158914; DOI=10.1016/j.bbadis.2004.01.008;
RA   Hueso M., Beltran V., Moreso F., Ciriero E., Fulladosa X., Grinyo J.M.,
RA   Seron D., Navarro E.;
RT   "Splicing alterations in human renal allografts: detection of a new splice
RT   variant of protein kinase Par1/Emk1 whose expression is associated with an
RT   increase of inflammation in protocol biopsies of transplanted patients.";
RL   Biochim. Biophys. Acta 1689:58-65(2004).
RN   [10] {ECO:0000305}
RP   FUNCTION, ACTIVITY REGULATION, PHOSPHORYLATION AT THR-208, AND MUTAGENESIS
RP   OF THR-208.
RX   PubMed=14976552; DOI=10.1038/sj.emboj.7600110;
RA   Lizcano J.M., Goeransson O., Toth R., Deak M., Morrice N.A., Boudeau J.,
RA   Hawley S.A., Udd L., Maekelae T.P., Hardie D.G., Alessi D.R.;
RT   "LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily,
RT   including MARK/PAR-1.";
RL   EMBO J. 23:833-843(2004).
RN   [11] {ECO:0000305}
RP   FUNCTION.
RX   PubMed=15365179; DOI=10.1073/pnas.0403684101;
RA   Cohen D., Rodriguez-Boulan E., Musch A.;
RT   "Par-1 promotes a hepatic mode of apical protein trafficking in MDCK
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:13792-13797(2004).
RN   [12]
RP   PHOSPHORYLATION AT THR-596, MUTAGENESIS OF THR-596, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=15084291; DOI=10.1016/j.cub.2004.04.007;
RA   Hurov J.B., Watkins J.L., Piwnica-Worms H.;
RT   "Atypical PKC phosphorylates PAR-1 kinases to regulate localization and
RT   activity.";
RL   Curr. Biol. 14:736-741(2004).
RN   [13] {ECO:0000305}
RP   FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION AT THR-596, MUTAGENESIS OF
RP   THR-596, AND INTERACTION WITH YWHAZ.
RX   PubMed=15324659; DOI=10.1016/j.cub.2004.08.021;
RA   Suzuki A., Hirata M., Kamimura K., Maniwa R., Yamanaka T., Mizuno K.,
RA   Kishikawa M., Hirose H., Amano Y., Izumi N., Miwa Y., Ohno S.;
RT   "aPKC acts upstream of PAR-1b in both the establishment and maintenance of
RT   mammalian epithelial polarity.";
RL   Curr. Biol. 14:1425-1435(2004).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-486, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [15]
RP   FUNCTION IN PHOSPHORYLATION OF RAB11FIP2.
RX   PubMed=16775013; DOI=10.1091/mbc.e05-08-0736;
RA   Ducharme N.A., Hales C.M., Lapierre L.A., Ham A.J., Oztan A., Apodaca G.,
RA   Goldenring J.R.;
RT   "MARK2/EMK1/Par-1Balpha phosphorylation of Rab11-family interacting protein
RT   2 is necessary for the timely establishment of polarity in Madin-Darby
RT   canine kidney cells.";
RL   Mol. Biol. Cell 17:3625-3637(2006).
RN   [16]
RP   FUNCTION IN PHOSPHORYLATION OF HDAC7.
RX   PubMed=16980613; DOI=10.1128/mcb.00231-06;
RA   Dequiedt F., Martin M., Von Blume J., Vertommen D., Lecomte E., Mari N.,
RA   Heinen M.F., Bachmann M., Twizere J.C., Huang M.C., Rider M.H.,
RA   Piwnica-Worms H., Seufferlein T., Kettmann R.;
RT   "New role for hPar-1 kinases EMK and C-TAK1 in regulating localization and
RT   activity of class IIa histone deacetylases.";
RL   Mol. Cell. Biol. 26:7086-7102(2006).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-456, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [18]
RP   INTERACTION WITH H.PYLORI CAGA (MICROBIAL INFECTION).
RX   PubMed=17507984; DOI=10.1038/nature05765;
RA   Saadat I., Higashi H., Obuse C., Umeda M., Murata-Kamiya N., Saito Y.,
RA   Lu H., Ohnishi N., Azuma T., Suzuki A., Ohno S., Hatakeyama M.;
RT   "Helicobacter pylori CagA targets PAR1/MARK kinase to disrupt epithelial
RT   cell polarity.";
RL   Nature 447:330-333(2007).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-456 AND SER-486, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-456, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-409; SER-456; SER-486 AND
RP   SER-493, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [22]
RP   FUNCTION IN PHOSPHORYLATION OF CRTC2.
RX   PubMed=18626018; DOI=10.1073/pnas.0800796105;
RA   Jansson D., Ng A.C., Fu A., Depatie C., Al Azzabi M., Screaton R.A.;
RT   "Glucose controls CREB activity in islet cells via regulated
RT   phosphorylation of TORC2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10161-10166(2008).
RN   [23]
RP   DOMAIN UBA.
RX   PubMed=16396636; DOI=10.1042/bj20051844;
RA   Jaleel M., Villa F., Deak M., Toth R., Prescott A.R., Van Aalten D.M.,
RA   Alessi D.R.;
RT   "The ubiquitin-associated domain of AMPK-related kinases regulates
RT   conformation and LKB1-mediated phosphorylation and activation.";
RL   Biochem. J. 394:545-555(2006).
RN   [24]
RP   INTERACTION WITH YWHAB; YWHAG AND YWHAQ.
RX   PubMed=16959763; DOI=10.1074/mcp.m600147-mcp200;
RA   Angrand P.O., Segura I., Voelkel P., Ghidelli S., Terry R., Brajenovic M.,
RA   Vintersten K., Klein R., Superti-Furga G., Drewes G., Kuster B.,
RA   Bouwmeester T., Acker-Palmer A.;
RT   "Transgenic mouse proteomics identifies new 14-3-3-associated proteins
RT   involved in cytoskeletal rearrangements and cell signaling.";
RL   Mol. Cell. Proteomics 5:2211-2227(2006).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-569, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT SER-376 (ISOFORMS 13 AND 14), PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT SER-409 (ISOFORMS 15 AND 16), AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-208; SER-409; SER-456;
RP   SER-486 AND SER-722, PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-376
RP   (ISOFORMS 13 AND 14), PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-409
RP   (ISOFORMS 15 AND 16), AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [28]
RP   FUNCTION IN PHOSPHORYLATION OF KIF13B.
RX   PubMed=20194617; DOI=10.1128/mcb.01181-09;
RA   Yoshimura Y., Terabayashi T., Miki H.;
RT   "Par1b/MARK2 phosphorylates kinesin-like motor protein GAKIN/KIF13B to
RT   regulate axon formation.";
RL   Mol. Cell. Biol. 30:2206-2219(2010).
RN   [29]
RP   REVIEW.
RX   PubMed=19559622; DOI=10.1016/j.tibs.2009.03.008;
RA   Matenia D., Mandelkow E.M.;
RT   "The tau of MARK: a polarized view of the cytoskeleton.";
RL   Trends Biochem. Sci. 34:332-342(2009).
RN   [30]
RP   REVIEW.
RX   PubMed=20071654; DOI=10.1096/fj.09-148064;
RA   Marx A., Nugoor C., Panneerselvam S., Mandelkow E.;
RT   "Structure and function of polarity-inducing kinase family MARK/Par-1
RT   within the branch of AMPK/Snf1-related kinases.";
RL   FASEB J. 24:1637-1648(2010).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [32]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-40; SER-486 AND SER-619, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [34]
RP   INTERACTION WITH MTCL1, AND SUBCELLULAR LOCATION.
RX   PubMed=23902687; DOI=10.1242/jcs.127845;
RA   Sato Y., Akitsu M., Amano Y., Yamashita K., Ide M., Shimada K.,
RA   Yamashita A., Hirano H., Arakawa N., Maki T., Hayashi I., Ohno S.,
RA   Suzuki A.;
RT   "The novel PAR-1-binding protein MTCL1 has crucial roles in organizing
RT   microtubules in polarizing epithelial cells.";
RL   J. Cell Sci. 126:4671-4683(2013).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-40; SER-456; THR-467;
RP   SER-486; SER-569; SER-571; SER-592; THR-596 AND SER-619, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [36]
RP   FUNCTION, INTERACTION WITH MAPT, AND SUBCELLULAR LOCATION.
RX   PubMed=23666762; DOI=10.1007/s12017-013-8232-3;
RA   Gu G.J., Lund H., Wu D., Blokzijl A., Classon C., von Euler G.,
RA   Landegren U., Sunnemark D., Kamali-Moghaddam M.;
RT   "Role of individual MARK isoforms in phosphorylation of tau at Ser262 in
RT   Alzheimer's disease.";
RL   NeuroMolecular Med. 15:458-469(2013).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 49-363 IN COMPLEX WITH H.PYLORI
RP   CAGA PEPTIDE INHIBITOR.
RX   PubMed=19966800; DOI=10.1038/nsmb.1705;
RA   Nesic D., Miller M.C., Quinkert Z.T., Stein M., Chait B.T., Stebbins C.E.;
RT   "Helicobacter pylori CagA inhibits PAR1-MARK family kinases by mimicking
RT   host substrates.";
RL   Nat. Struct. Mol. Biol. 17:130-132(2010).
CC   -!- FUNCTION: Serine/threonine-protein kinase (PubMed:23666762). Involved
CC       in cell polarity and microtubule dynamics regulation. Phosphorylates
CC       CRTC2/TORC2, DCX, HDAC7, KIF13B, MAP2, MAP4 and RAB11FIP2.
CC       Phosphorylates the microtubule-associated protein MAPT/TAU
CC       (PubMed:23666762). Plays a key role in cell polarity by phosphorylating
CC       the microtubule-associated proteins MAP2, MAP4 and MAPT/TAU at KXGS
CC       motifs, causing detachment from microtubules, and their disassembly.
CC       Regulates epithelial cell polarity by phosphorylating RAB11FIP2.
CC       Involved in the regulation of neuronal migration through its dual
CC       activities in regulating cellular polarity and microtubule dynamics,
CC       possibly by phosphorylating and regulating DCX. Regulates axogenesis by
CC       phosphorylating KIF13B, promoting interaction between KIF13B and 14-3-3
CC       and inhibiting microtubule-dependent accumulation of KIF13B. Also
CC       required for neurite outgrowth and establishment of neuronal polarity.
CC       Regulates localization and activity of some histone deacetylases by
CC       mediating phosphorylation of HDAC7, promoting subsequent interaction
CC       between HDAC7 and 14-3-3 and export from the nucleus. Also acts as a
CC       positive regulator of the Wnt signaling pathway, probably by mediating
CC       phosphorylation of dishevelled proteins (DVL1, DVL2 and/or DVL3).
CC       Modulates the developmental decision to build a columnar versus a
CC       hepatic epithelial cell apparently by promoting a switch from a direct
CC       to a transcytotic mode of apical protein delivery. Essential for the
CC       asymmetric development of membrane domains of polarized epithelial
CC       cells. {ECO:0000269|PubMed:11433294, ECO:0000269|PubMed:12429843,
CC       ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:15158914,
CC       ECO:0000269|PubMed:15324659, ECO:0000269|PubMed:15365179,
CC       ECO:0000269|PubMed:16775013, ECO:0000269|PubMed:16980613,
CC       ECO:0000269|PubMed:18626018, ECO:0000269|PubMed:20194617,
CC       ECO:0000269|PubMed:23666762}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:14976552};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:14976552};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[tau protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [tau protein]; Xref=Rhea:RHEA:12801, Rhea:RHEA-COMP:13701, Rhea:RHEA-
CC         COMP:13702, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.26;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[tau protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[tau protein]; Xref=Rhea:RHEA:53904, Rhea:RHEA-COMP:13703,
CC         Rhea:RHEA-COMP:13704, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.26;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- ACTIVITY REGULATION: Inhibited by PAK5; inhibition is independent of
CC       the kinase activity of PAK5 (By similarity). Activated by
CC       phosphorylation on Thr-208. Inhibited by phosphorylation at Ser-212 and
CC       Thr-596. Inhibited by hymenialdisine. Specifically inhibited by the
CC       H.pylori CagA peptide FPLKRHDKVDDLSK that mimics host substrates and
CC       binds to the kinase substrate-binding site. {ECO:0000250,
CC       ECO:0000269|PubMed:12429843, ECO:0000269|PubMed:14976552}.
CC   -!- SUBUNIT: Homodimer. Interacts with PAK5; leading to inhibit the protein
CC       kinase activity (By similarity). Interacts with MAPT/TAU
CC       (PubMed:23666762). Interacts with MTCL1 isoform 1; the interaction is
CC       direct and increases MARK2 microtubule-binding ability
CC       (PubMed:23902687). Interacts (when phosphorylated at Thr-596) with
CC       YWHAZ (PubMed:15324659). Interacts with YWHAB, YWHAG and YWHAQ
CC       (PubMed:16959763). {ECO:0000250|UniProtKB:O08679,
CC       ECO:0000269|PubMed:15324659, ECO:0000269|PubMed:16959763,
CC       ECO:0000269|PubMed:23666762, ECO:0000269|PubMed:23902687}.
CC   -!- SUBUNIT: (Microbial infection) In case of infection, interacts with
CC       H.pylori CagA, leading to inhibit kinase activity and junctional and
CC       polarity defects. {ECO:0000269|PubMed:17507984,
CC       ECO:0000269|PubMed:19966800}.
CC   -!- INTERACTION:
CC       Q7KZI7; Q9BYG4: PARD6G; NbExp=2; IntAct=EBI-516560, EBI-295417;
CC       Q7KZI7; P31946: YWHAB; NbExp=4; IntAct=EBI-516560, EBI-359815;
CC       Q7KZI7; P61981: YWHAG; NbExp=4; IntAct=EBI-516560, EBI-359832;
CC       Q7KZI7; Q04917: YWHAH; NbExp=10; IntAct=EBI-516560, EBI-306940;
CC       Q7KZI7; P63104: YWHAZ; NbExp=8; IntAct=EBI-516560, EBI-347088;
CC       Q7KZI7; P55980: cagA; Xeno; NbExp=4; IntAct=EBI-516560, EBI-528104;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Peripheral membrane protein.
CC       Cytoplasm. Lateral cell membrane. Cytoplasm, cytoskeleton. Cell
CC       projection, dendrite {ECO:0000269|PubMed:23666762}. Cytoplasm
CC       {ECO:0000269|PubMed:23666762}. Note=Phosphorylation at Thr-596 by
CC       PRKCZ/aPKC and subsequent interaction with 14-3-3 protein YWHAZ
CC       promotes relocation from the cell membrane to the cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=16;
CC       Name=1 {ECO:0000305}; Synonyms=Alpha;
CC         IsoId=Q7KZI7-1; Sequence=Displayed;
CC       Name=2 {ECO:0000269|PubMed:9730619};
CC         IsoId=Q7KZI7-2; Sequence=VSP_051705, VSP_051706;
CC       Name=3 {ECO:0000269|PubMed:9730619};
CC         IsoId=Q7KZI7-3; Sequence=VSP_051705, VSP_051707;
CC       Name=4 {ECO:0000269|PubMed:11433294}; Synonyms=Par-1Balpha
CC       {ECO:0000269|PubMed:11433294};
CC         IsoId=Q7KZI7-4; Sequence=VSP_051706, VSP_051707;
CC       Name=5;
CC         IsoId=Q7KZI7-5; Sequence=VSP_051706, VSP_051708;
CC       Name=6 {ECO:0000305}; Synonyms=Beta;
CC         IsoId=Q7KZI7-6; Sequence=VSP_051705;
CC       Name=7 {ECO:0000305};
CC         IsoId=Q7KZI7-7; Sequence=VSP_051705, VSP_051706, VSP_051707;
CC       Name=8 {ECO:0000305};
CC         IsoId=Q7KZI7-8; Sequence=VSP_051707;
CC       Name=9 {ECO:0000305};
CC         IsoId=Q7KZI7-9; Sequence=VSP_051706;
CC       Name=10 {ECO:0000305};
CC         IsoId=Q7KZI7-10; Sequence=VSP_051705, VSP_051706, VSP_051708;
CC       Name=11 {ECO:0000305};
CC         IsoId=Q7KZI7-11; Sequence=VSP_051708;
CC       Name=12 {ECO:0000305};
CC         IsoId=Q7KZI7-12; Sequence=VSP_051705, VSP_051708;
CC       Name=13;
CC         IsoId=Q7KZI7-13; Sequence=VSP_051705, VSP_039872, VSP_051706,
CC                                   VSP_051707;
CC       Name=14;
CC         IsoId=Q7KZI7-14; Sequence=VSP_051705, VSP_039872, VSP_051707;
CC       Name=15;
CC         IsoId=Q7KZI7-15; Sequence=VSP_039872, VSP_051706, VSP_041853;
CC       Name=16;
CC         IsoId=Q7KZI7-16; Sequence=VSP_039872, VSP_051706, VSP_051707;
CC   -!- TISSUE SPECIFICITY: High levels of expression in heart, brain, skeletal
CC       muscle and pancreas, lower levels observed in lung, liver and kidney.
CC       {ECO:0000269|PubMed:9730619}.
CC   -!- DOMAIN: The UBA domain does not seem to bind ubiquitin and ubiquitin-
CC       like and might play a role in regulating the enzyme conformation and
CC       localization. Activation of the kinase activity following
CC       phosphorylation at Thr-208 is accompanied by a conformational change
CC       that alters the orientation of the UBA domain with respect to the
CC       catalytic domain. {ECO:0000269|PubMed:16396636}.
CC   -!- DOMAIN: The KA1 domain mediates binding to phospholipids and targeting
CC       to membranes. {ECO:0000250}.
CC   -!- PTM: Autophosphorylated. Phosphorylated at Thr-208 by STK11/LKB1 in
CC       complex with STE20-related adapter-alpha (STRADA) pseudo kinase and
CC       CAB39. Phosphorylation at Thr-208 by TAOK1 activates the kinase
CC       activity, leading to phosphorylation and detachment of MAPT/TAU from
CC       microtubules. Phosphorylation at Ser-212 by GSK3-beta (GSK3B) inhibits
CC       the kinase activity. Phosphorylation by CaMK1 promotes activity and is
CC       required to promote neurite outgrowth. Phosphorylation at Thr-596 by
CC       PRKCZ/aPKC in polarized epithelial cells inhibits the kinase activity
CC       and promotes binding to 14-3-3 protein YWHAZ, leading to relocation
CC       from cell membrane to cytoplasm. {ECO:0000269|PubMed:14976552,
CC       ECO:0000269|PubMed:15084291, ECO:0000269|PubMed:15324659}.
CC   -!- MISCELLANEOUS: [Isoform 1]: Produced by alternative promoter usage.
CC   -!- MISCELLANEOUS: [Isoform 2]: Produced by alternative splicing of isoform
CC       6. {ECO:0000269|PubMed:9730619}.
CC   -!- MISCELLANEOUS: [Isoform 3]: Produced by alternative splicing of isoform
CC       6. {ECO:0000269|PubMed:9730619}.
CC   -!- MISCELLANEOUS: [Isoform 4]: Produced by alternative splicing of isoform
CC       1. {ECO:0000269|PubMed:11433294}.
CC   -!- MISCELLANEOUS: [Isoform 5]: Produced by alternative splicing of isoform
CC       1. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 6]: Produced by alternative promoter usage.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 7]: Produced by alternative splicing of isoform
CC       6. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 8]: Produced by alternative splicing of isoform
CC       1. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 9]: Produced by alternative splicing of isoform
CC       1. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 10]: Produced by alternative splicing of
CC       isoform 6. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 11]: Produced by alternative splicing of
CC       isoform 1. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 12]: Produced by alternative splicing of
CC       isoform 6. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 13]: Produced by alternative splicing of
CC       isoform 6. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 14]: Produced by alternative splicing of
CC       isoform 6. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 15]: Produced by alternative splicing of
CC       isoform 1. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 16]: Produced by alternative splicing of
CC       isoform 1. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr
CC       protein kinase family. SNF1 subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAK82368.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X97630; CAA66229.1; -; mRNA.
DR   EMBL; AB188493; BAD37141.1; -; mRNA.
DR   EMBL; BT007342; AAP36006.1; -; mRNA.
DR   EMBL; AP003780; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC008771; AAH08771.2; -; mRNA.
DR   EMBL; BC084540; AAH84540.1; -; mRNA.
DR   EMBL; AF387638; AAK82368.1; ALT_INIT; mRNA.
DR   EMBL; Z25427; CAA80914.1; -; mRNA.
DR   CCDS; CCDS41665.1; -. [Q7KZI7-14]
DR   CCDS; CCDS53649.1; -. [Q7KZI7-1]
DR   CCDS; CCDS53650.1; -. [Q7KZI7-5]
DR   CCDS; CCDS53651.1; -. [Q7KZI7-15]
DR   CCDS; CCDS8051.2; -. [Q7KZI7-16]
DR   PIR; G01025; G01025.
DR   PIR; I38217; I38217.
DR   RefSeq; NP_001034558.2; NM_001039469.2. [Q7KZI7-1]
DR   RefSeq; NP_001156768.1; NM_001163296.1. [Q7KZI7-5]
DR   RefSeq; NP_001156769.1; NM_001163297.1. [Q7KZI7-15]
DR   RefSeq; NP_004945.4; NM_004954.4. [Q7KZI7-16]
DR   RefSeq; NP_059672.2; NM_017490.3. [Q7KZI7-14]
DR   PDB; 3IEC; X-ray; 2.20 A; A/B/C/D=49-363.
DR   PDB; 5EAK; X-ray; 2.80 A; A/B=39-364.
DR   PDB; 5KZ7; X-ray; 3.20 A; A/B=39-364.
DR   PDB; 5KZ8; X-ray; 3.21 A; A/B=39-364.
DR   PDBsum; 3IEC; -.
DR   PDBsum; 5EAK; -.
DR   PDBsum; 5KZ7; -.
DR   PDBsum; 5KZ8; -.
DR   AlphaFoldDB; Q7KZI7; -.
DR   SASBDB; Q7KZI7; -.
DR   SMR; Q7KZI7; -.
DR   BioGRID; 108326; 239.
DR   CORUM; Q7KZI7; -.
DR   DIP; DIP-31321N; -.
DR   IntAct; Q7KZI7; 101.
DR   MINT; Q7KZI7; -.
DR   STRING; 9606.ENSP00000385751; -.
DR   BindingDB; Q7KZI7; -.
DR   ChEMBL; CHEMBL3831; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q7KZI7; -.
DR   GlyGen; Q7KZI7; 3 sites, 1 O-linked glycan (1 site).
DR   iPTMnet; Q7KZI7; -.
DR   PhosphoSitePlus; Q7KZI7; -.
DR   BioMuta; MARK2; -.
DR   DMDM; 62510922; -.
DR   EPD; Q7KZI7; -.
DR   jPOST; Q7KZI7; -.
DR   MassIVE; Q7KZI7; -.
DR   MaxQB; Q7KZI7; -.
DR   PaxDb; Q7KZI7; -.
DR   PeptideAtlas; Q7KZI7; -.
DR   PRIDE; Q7KZI7; -.
DR   ProteomicsDB; 68707; -. [Q7KZI7-1]
DR   ProteomicsDB; 68708; -. [Q7KZI7-10]
DR   ProteomicsDB; 68709; -. [Q7KZI7-11]
DR   ProteomicsDB; 68710; -. [Q7KZI7-12]
DR   ProteomicsDB; 68711; -. [Q7KZI7-13]
DR   ProteomicsDB; 68712; -. [Q7KZI7-14]
DR   ProteomicsDB; 68713; -. [Q7KZI7-15]
DR   ProteomicsDB; 68714; -. [Q7KZI7-16]
DR   ProteomicsDB; 68715; -. [Q7KZI7-2]
DR   ProteomicsDB; 68716; -. [Q7KZI7-3]
DR   ProteomicsDB; 68717; -. [Q7KZI7-4]
DR   ProteomicsDB; 68718; -. [Q7KZI7-5]
DR   ProteomicsDB; 68719; -. [Q7KZI7-6]
DR   ProteomicsDB; 68720; -. [Q7KZI7-7]
DR   ProteomicsDB; 68721; -. [Q7KZI7-8]
DR   ProteomicsDB; 68722; -. [Q7KZI7-9]
DR   Antibodypedia; 15193; 486 antibodies from 40 providers.
DR   DNASU; 2011; -.
DR   Ensembl; ENST00000350490.11; ENSP00000294247.9; ENSG00000072518.22. [Q7KZI7-15]
DR   Ensembl; ENST00000361128.9; ENSP00000355091.5; ENSG00000072518.22. [Q7KZI7-5]
DR   Ensembl; ENST00000402010.8; ENSP00000385751.2; ENSG00000072518.22. [Q7KZI7-1]
DR   Ensembl; ENST00000408948.7; ENSP00000386128.3; ENSG00000072518.22. [Q7KZI7-13]
DR   Ensembl; ENST00000508192.5; ENSP00000425765.1; ENSG00000072518.22. [Q7KZI7-16]
DR   Ensembl; ENST00000509502.6; ENSP00000423974.2; ENSG00000072518.22. [Q7KZI7-14]
DR   Ensembl; ENST00000513765.7; ENSP00000421075.3; ENSG00000072518.22. [Q7KZI7-8]
DR   GeneID; 2011; -.
DR   KEGG; hsa:2011; -.
DR   MANE-Select; ENST00000402010.8; ENSP00000385751.2; NM_001039469.3; NP_001034558.2.
DR   UCSC; uc001nxv.5; human. [Q7KZI7-1]
DR   CTD; 2011; -.
DR   DisGeNET; 2011; -.
DR   GeneCards; MARK2; -.
DR   HGNC; HGNC:3332; MARK2.
DR   HPA; ENSG00000072518; Low tissue specificity.
DR   MIM; 600526; gene.
DR   neXtProt; NX_Q7KZI7; -.
DR   OpenTargets; ENSG00000072518; -.
DR   PharmGKB; PA35047; -.
DR   VEuPathDB; HostDB:ENSG00000072518; -.
DR   eggNOG; KOG0586; Eukaryota.
DR   GeneTree; ENSGT00940000155031; -.
DR   HOGENOM; CLU_000288_157_5_1; -.
DR   InParanoid; Q7KZI7; -.
DR   OMA; MSASMHP; -.
DR   OrthoDB; 1127668at2759; -.
DR   PhylomeDB; Q7KZI7; -.
DR   TreeFam; TF315213; -.
DR   PathwayCommons; Q7KZI7; -.
DR   SignaLink; Q7KZI7; -.
DR   SIGNOR; Q7KZI7; -.
DR   BioGRID-ORCS; 2011; 140 hits in 1129 CRISPR screens.
DR   ChiTaRS; MARK2; human.
DR   EvolutionaryTrace; Q7KZI7; -.
DR   GeneWiki; MARK2; -.
DR   GenomeRNAi; 2011; -.
DR   Pharos; Q7KZI7; Tchem.
DR   PRO; PR:Q7KZI7; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q7KZI7; protein.
DR   Bgee; ENSG00000072518; Expressed in lower esophagus mucosa and 111 other tissues.
DR   ExpressionAtlas; Q7KZI7; baseline and differential.
DR   Genevisible; Q7KZI7; HS.
DR   GO; GO:0005884; C:actin filament; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0030425; C:dendrite; IDA:UniProtKB.
DR   GO; GO:0016328; C:lateral plasma membrane; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IMP:UniProtKB.
DR   GO; GO:0097427; C:microtubule bundle; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL.
DR   GO; GO:0008289; F:lipid binding; IEA:UniProtKB-KW.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0030295; F:protein kinase activator activity; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0048156; F:tau protein binding; ISS:ARUK-UCL.
DR   GO; GO:0050321; F:tau-protein kinase activity; IMP:UniProtKB.
DR   GO; GO:0032147; P:activation of protein kinase activity; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0000422; P:autophagy of mitochondrion; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0061564; P:axon development; ISS:ARUK-UCL.
DR   GO; GO:0030010; P:establishment of cell polarity; IDA:UniProtKB.
DR   GO; GO:0071963; P:establishment or maintenance of cell polarity regulating cell shape; ISS:ARUK-UCL.
DR   GO; GO:0045197; P:establishment or maintenance of epithelial cell apical/basal polarity; IDA:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB.
DR   GO; GO:0000226; P:microtubule cytoskeleton organization; IBA:GO_Central.
DR   GO; GO:0051646; P:mitochondrion localization; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0001764; P:neuron migration; ISS:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:ARUK-UCL.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IDA:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; ISS:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0050770; P:regulation of axonogenesis; IMP:UniProtKB.
DR   GO; GO:0051493; P:regulation of cytoskeleton organization; ISS:UniProtKB.
DR   GO; GO:1904526; P:regulation of microtubule binding; ISS:ARUK-UCL.
DR   GO; GO:0070507; P:regulation of microtubule cytoskeleton organization; IDA:ARUK-UCL.
DR   GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW.
DR   InterPro; IPR028375; KA1/Ssp2_C.
DR   InterPro; IPR001772; KA1_dom.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR015940; UBA.
DR   Pfam; PF02149; KA1; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00627; UBA; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SMART; SM00165; UBA; 1.
DR   SUPFAM; SSF103243; SSF103243; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50032; KA1; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS50030; UBA; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative promoter usage; Alternative splicing;
KW   ATP-binding; Cell membrane; Cell projection; Cytoplasm; Cytoskeleton;
KW   Developmental protein; Differentiation; Kinase; Lipid-binding; Magnesium;
KW   Membrane; Metal-binding; Nucleotide-binding; Phosphoprotein;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase;
KW   Wnt signaling pathway.
FT   CHAIN           1..788
FT                   /note="Serine/threonine-protein kinase MARK2"
FT                   /id="PRO_0000086301"
FT   DOMAIN          53..304
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          323..362
FT                   /note="UBA"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00212"
FT   DOMAIN          739..788
FT                   /note="KA1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00565"
FT   REGION          1..46
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          373..632
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        378..407
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        414..430
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        431..447
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        465..632
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        175
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250|UniProtKB:Q9H0K1,
FT                   ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE-
FT                   ProRule:PRU10027"
FT   BINDING         59..67
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:Q9H0K1,
FT                   ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         82
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:O08678,
FT                   ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         40
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         58
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:O08679"
FT   MOD_RES         91
FT                   /note="Phosphoserine; by CaMK1"
FT                   /evidence="ECO:0000250|UniProtKB:O08679"
FT   MOD_RES         92
FT                   /note="Phosphoserine; by CaMK1"
FT                   /evidence="ECO:0000250|UniProtKB:O08679"
FT   MOD_RES         93
FT                   /note="Phosphoserine; by CaMK1"
FT                   /evidence="ECO:0000250|UniProtKB:O08679"
FT   MOD_RES         208
FT                   /note="Phosphothreonine; by LKB1 and TAOK1"
FT                   /evidence="ECO:0000269|PubMed:14976552,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         212
FT                   /note="Phosphoserine; by GSK3-beta"
FT                   /evidence="ECO:0000250|UniProtKB:O08679"
FT   MOD_RES         274
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:O08679"
FT   MOD_RES         275
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:O08679"
FT   MOD_RES         294
FT                   /note="Phosphothreonine; by CaMK1"
FT                   /evidence="ECO:0000250|UniProtKB:O08679"
FT   MOD_RES         409
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         456
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:18088087, ECO:0007744|PubMed:18220336,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         467
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         486
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18220336, ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         493
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         569
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         571
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         592
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         596
FT                   /note="Phosphothreonine; by PKC/PRKCZ"
FT                   /evidence="ECO:0000269|PubMed:15084291,
FT                   ECO:0000269|PubMed:15324659, ECO:0007744|PubMed:23186163"
FT   MOD_RES         619
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         722
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   VAR_SEQ         1..33
FT                   /note="Missing (in isoform 2, isoform 3, isoform 6, isoform
FT                   7, isoform 10, isoform 12, isoform 13 and isoform 14)"
FT                   /evidence="ECO:0000303|PubMed:9730619, ECO:0000303|Ref.3"
FT                   /id="VSP_051705"
FT   VAR_SEQ         412
FT                   /note="Missing (in isoform 13, isoform 14, isoform 15 and
FT                   isoform 16)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_039872"
FT   VAR_SEQ         505..558
FT                   /note="Missing (in isoform 2, isoform 4, isoform 5, isoform
FT                   7, isoform 9, isoform 10, isoform 13, isoform 15 and
FT                   isoform 16)"
FT                   /evidence="ECO:0000303|PubMed:11433294,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:9730619,
FT                   ECO:0000303|Ref.2"
FT                   /id="VSP_051706"
FT   VAR_SEQ         644..652
FT                   /note="Missing (in isoform 3, isoform 4, isoform 7, isoform
FT                   8, isoform 13, isoform 14 and isoform 16)"
FT                   /evidence="ECO:0000303|PubMed:11433294,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:9730619"
FT                   /id="VSP_051707"
FT   VAR_SEQ         645..668
FT                   /note="Missing (in isoform 15)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_041853"
FT   VAR_SEQ         654..668
FT                   /note="Missing (in isoform 5, isoform 11, isoform 10 and
FT                   isoform 12)"
FT                   /evidence="ECO:0000303|PubMed:11433294,
FT                   ECO:0000303|PubMed:9730619, ECO:0000303|Ref.2"
FT                   /id="VSP_051708"
FT   MUTAGEN         208
FT                   /note="T->A: Prevents phosphorylation and activation by
FT                   STK11/LKB1 complex."
FT                   /evidence="ECO:0000269|PubMed:14976552"
FT   MUTAGEN         596
FT                   /note="T->A: Loss of membrane dissociation and binding to
FT                   YWHAZ."
FT                   /evidence="ECO:0000269|PubMed:15084291,
FT                   ECO:0000269|PubMed:15324659"
FT   CONFLICT        192
FT                   /note="A -> G (in Ref. 7; CAA80914)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        236
FT                   /note="L -> C (in Ref. 7; CAA80914)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        389..390
FT                   /note="PS -> QF (in Ref. 1; CAA66229)"
FT                   /evidence="ECO:0000305"
FT   STRAND          53..60
FT                   /evidence="ECO:0007829|PDB:3IEC"
FT   STRAND          66..72
FT                   /evidence="ECO:0007829|PDB:3IEC"
FT   TURN            73..75
FT                   /evidence="ECO:0007829|PDB:3IEC"
FT   STRAND          78..86
FT                   /evidence="ECO:0007829|PDB:3IEC"
FT   HELIX           91..106
FT                   /evidence="ECO:0007829|PDB:3IEC"
FT   STRAND          115..120
FT                   /evidence="ECO:0007829|PDB:3IEC"
FT   STRAND          122..129
FT                   /evidence="ECO:0007829|PDB:3IEC"
FT   HELIX           137..144
FT                   /evidence="ECO:0007829|PDB:3IEC"
FT   HELIX           149..168
FT                   /evidence="ECO:0007829|PDB:3IEC"
FT   HELIX           178..180
FT                   /evidence="ECO:0007829|PDB:3IEC"
FT   STRAND          181..183
FT                   /evidence="ECO:0007829|PDB:3IEC"
FT   STRAND          189..191
FT                   /evidence="ECO:0007829|PDB:3IEC"
FT   HELIX           213..215
FT                   /evidence="ECO:0007829|PDB:3IEC"
FT   HELIX           218..221
FT                   /evidence="ECO:0007829|PDB:3IEC"
FT   HELIX           228..245
FT                   /evidence="ECO:0007829|PDB:3IEC"
FT   HELIX           255..264
FT                   /evidence="ECO:0007829|PDB:3IEC"
FT   HELIX           275..284
FT                   /evidence="ECO:0007829|PDB:3IEC"
FT   HELIX           289..291
FT                   /evidence="ECO:0007829|PDB:3IEC"
FT   HELIX           295..299
FT                   /evidence="ECO:0007829|PDB:3IEC"
FT   HELIX           302..305
FT                   /evidence="ECO:0007829|PDB:3IEC"
FT   STRAND          309..311
FT                   /evidence="ECO:0007829|PDB:5KZ7"
FT   HELIX           326..334
FT                   /evidence="ECO:0007829|PDB:3IEC"
FT   HELIX           339..347
FT                   /evidence="ECO:0007829|PDB:3IEC"
FT   HELIX           353..361
FT                   /evidence="ECO:0007829|PDB:3IEC"
FT   MOD_RES         Q7KZI7-13:376
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         Q7KZI7-14:376
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         Q7KZI7-15:409
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         Q7KZI7-16:409
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19369195"
SQ   SEQUENCE   788 AA;  87911 MW;  F307BF4DDB543A70 CRC64;
     MSSARTPLPT LNERDTEQPT LGHLDSKPSS KSNMIRGRNS ATSADEQPHI GNYRLLKTIG
     KGNFAKVKLA RHILTGKEVA VKIIDKTQLN SSSLQKLFRE VRIMKVLNHP NIVKLFEVIE
     TEKTLYLVME YASGGEVFDY LVAHGRMKEK EARAKFRQIV SAVQYCHQKF IVHRDLKAEN
     LLLDADMNIK IADFGFSNEF TFGNKLDTFC GSPPYAAPEL FQGKKYDGPE VDVWSLGVIL
     YTLVSGSLPF DGQNLKELRE RVLRGKYRIP FYMSTDCENL LKKFLILNPS KRGTLEQIMK
     DRWMNVGHED DELKPYVEPL PDYKDPRRTE LMVSMGYTRE EIQDSLVGQR YNEVMATYLL
     LGYKSSELEG DTITLKPRPS ADLTNSSAPS PSHKVQRSVS ANPKQRRFSD QAAGPAIPTS
     NSYSKKTQSN NAENKRPEED RESGRKASST AKVPASPLPG LERKKTTPTP STNSVLSTST
     NRSRNSPLLE RASLGQASIQ NGKDSLTMPG SRASTASASA AVSAARPRQH QKSMSASVHP
     NKASGLPPTE SNCEVPRPST APQRVPVASP SAHNISSSGG APDRTNFPRG VSSRSTFHAG
     QLRQVRDQQN LPYGVTPASP SGHSQGRRGA SGSIFSKFTS KFVRRNLSFR FARRNLNEPE
     SKDRVETLRP HVVGSGGNDK EKEEFREAKP RSLRFTWSMK TTSSMEPNEM MREIRKVLDA
     NSCQSELHEK YMLLCMHGTP GHEDFVQWEM EVCKLPRLSL NGVRFKRISG TSMAFKNIAS
     KIANELKL
//
